 |
|
|
 = Add Release to Briefcase |
| All 2008 Releases |
|---|
 |
ZIOPHARM Presents Positive Darinaparsin Phase II Data at ASH Meeting
Dec 8, 2008
|
10.8 KB
|
| |
SAN FRANCISCO, Dec 08, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that on December 6th
it presented positive data from a Phase II study of darinaparsin (ZinaparTM)
for the treatment of advanced lymphomas at the 50th American
Society of Hematology (ASH) Annual Meeting held in San Francisco,...
|
|
|
Jonathan Lewis, MD, PhD, Appointed to Scientific Advisory Council of the Hope Funds for Cancer Research
Dec 4, 2008
|
11.7 KB
|
| |
NEW YORK & NEWPORT, R.I., Dec 04, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) and the Hope Funds for Cancer
Research announced today that Jonathan Lewis, MD, PhD, Chief Executive
and Medical Officer of ZIOPHARM, has been appointed to the Hope Funds'
newly formed Scientific Advisory Council, a permanent com...
|
|
|
ZIOPHARM Oncology Presents Positive Data from Studies of Palifosfamide
Nov 17, 2008
|
10.5 KB
|
| |
LONDON--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP - News) announced today that it presented positive data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 14th Annual Connective Tissue Oncology Society (CTOS) meeting held in London, UK, November 13 to 15. Also presented was an update of the da...
|
|
|
ZIOPHARM Oncology to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Nov 5, 2008
|
9.4 KB
|
| |
NEW YORK, Nov 05, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 4:30 pm ET at the New York Palace Hotel in New York City. Dr. Lewis will provide a...
|
|
|
ZIOPHARM To Host Analyst & Institutional Investor Meeting
Nov 3, 2008
|
9.5 KB
|
| |
NEW YORK, Nov 03, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Company will host an analyst and institutional investor meeting on Thursday, November 20, 2008 from 7:30 A.M. to 10:00 A.M. Eastern Time in New York City.
The event will be moderated by Jonathan Lewis, MD, PhD, Chief Executive Officer of ZI...
|
|
|
ZIOPHARM Oncology Reports Third Quarter Financial Results
Oct 31, 2008
|
10.9 KB
|
| |
NEW YORK, Oct 31, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today its financial results for the three and nine-month period ending September 30, 2008.
The Company reported a lower net loss for the third quarter of 2008 of $5.5 million, or $(0.26) per share, compared with a net loss for the third quarter of 2007 of...
|
|
|
ZIOPHARM Oncology to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
Oct 27, 2008
|
9.5 KB
|
| |
NEW YORK, Oct 27, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Oppenheimer & Co. 19th Annual Healthcare Conference on Monday, November 3, 2008 at 3:20 pm ET at the Waldorf-Astoria Hotel in New York City. Dr. Lewis will provide an...
|
|
|
ZIOPHARM Presents Darinaparsin Molecular Mechanism of Action and Preliminary Oral Administration Phase I Clinical Data at the EORTC-NCI-AACR Symposium
Oct 23, 2008
|
10.5 KB
|
| |
GENEVA, Oct 23, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that it presented darinaparsin (ZIO-101) mechanism of action data as well as preliminary data from Phase I studies with oral administration at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
Data...
|
|
|
ZIOPHARM Receives Orphan Medicinal Product Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma
Oct 15, 2008
|
10.7 KB
|
| |
NEW YORK, Oct 15, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion regarding ZIOPHARM's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma...
|
|
|
ZIOPHARM Oncology to Present at Maxim Group Growth Investor Conference
Sep 30, 2008
|
8.1 KB
|
| |
NEW YORK, Sep 30, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Maxim Group Growth Investor Conference on Tuesday, October 7, 2008 at 3:30 pm ET in the Morosco room at the Grand Hyatt Hotel in New York, NY. Dr. Lewis will provide an overview of th...
|
|
|
ZIOPHARM Oncology to Present at the Third Annual JMP Securities Healthcare Focus Conference
Sep 29, 2008
|
8.1 KB
|
| |
NEW YORK, Sep 29, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 3:30 at Le Meridien Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and ...
|
|
|
ZIOPHARM Oncology to Present at UBS Global Life Sciences Conference
Sep 18, 2008
|
7.3 KB
|
| |
NEW YORK, Sep 18, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 25, 2008 at 12:30 pm ET at the Grand Hyatt Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its ...
|
|
|
ZIOPHARM Commences Randomized Phase II Study of Palifosfamide in Soft Tissue Sarcoma
Sep 5, 2008
|
9.7 KB
|
| |
NEW YORK, Sep 05, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that the first patient has been dosed in its international Phase II randomized controlled trial of palifosfamide (ZIO-201) in patients with soft-tissue sarcoma (STS): This is a Phase II multi-center, parallel group, randomized study of palIfosfamide pl...
|
|
|
ZIOPHARM Receives Notices of Allowance for European and U.S. Patents Covering Indibulin
Aug 18, 2008
|
8.6 KB
|
| |
NEW YORK, Aug 18, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it has received notice from the European Patent Office that it intends to grant a patent with claims covering certain pharmaceutical formulations of indibulin (ZIO-301) for oral administration and processes for manufacturing such formulations. The ...
|
|
|
Leukemia Journal Publishes Results from Darinaparsin Study
Aug 4, 2008
|
9.8 KB
|
| |
NEW YORK, Aug 04, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance publication issue of Leukemia, a Nature publication. The article, titled "A novel arsenical has antitumor activity toward As(2)O(3)-resist...
|
|
|
ZIOPHARM Oncology Reports Second Quarter Financial Results
Jul 31, 2008
|
10.1 KB
|
| |
NEW YORK, Jul 31, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today its financial results for the three and six-month periods ended June 30, 2008.
The Company reported a net loss for the second quarter of 2008 of $6.5 million, or $(0.31) per share, compared with a net loss for the second quarter of 2007 of $6.5 mill...
|
|
|
ZIOPHARM Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at AACR Centennial Conference
Jul 23, 2008
|
10.0 KB
|
| |
MONTEREY, Calif., Jul 23, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicin...
|
|
|
ZIOPHARM Announces Organizational Changes and New Appointments in Clinical and Regulatory
Jun 20, 2008
|
9.0 KB
|
| |
NEW YORK, Jun 20, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today changes and new appointments in its clinical and regulatory groups together with the departure of Brian Schwartz, MD, Chief Medical Officer, who will be leaving the Company as of July 11th to pursue other opportunities. His responsibilities as CMO will ...
|
|
|
ZIOPHARM Oncology to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Jun 5, 2008
|
7.7 KB
|
| |
NEW YORK, Jun 05, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on Thursday, June 12, 2008 at 3:00 pm ET in the Hubbard Room at the New York Palace Hotel in New ...
|
|
|
ZIOPHARM Receives Notices of Allowance for Two U.S. Patent Applications Covering Darinaparsin
May 13, 2008
|
9.0 KB
|
| |
NEW YORK, May 13, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office for patent applications numbered 11/252,966 and 11/349,043, covering claims for various organic arsenic compounds, including purified crystalline darinaparsin, glycolic ...
|
|
|
| |
Recent Releases
Sep 7, 2010
ZIOPHARM Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
Aug 4, 2010
ZIOPHARM Oncology to Present at the Canaccord Genuity 30th Annual Global Growth Conference
Jul 30, 2010
ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical Programs
more »
|
